Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Redhill Biopharma Ltd. for the month of June 2022, with a filing date of June 1, 2022. The report serves as a re-filing of Exhibit 99.1, an Exclusive License Agreement dated March 30, 2015, between the Company and Apogee Biotechnology Corp. The purpose of this filing is to transition the exhibit to comply with Item 601(b) of Regulation S-K, allowing the omission of confidential information without a confidential treatment request.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding contract exhibits and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The only change noted is the redaction of specific confidential information from the attached license agreement, which the Company states is not material but could cause competitive harm if disclosed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk disclosed relates to the competitive harm that could result from the public disclosure of the omitted confidential information within the license agreement.
Key Facts for Investor Verification
- The filing is a procedural update to refile a 2015 license agreement with redacted confidential terms.
- No financial data or operational updates are included in this specific Form 6-K.
- The omitted information is deemed immaterial to investors but sensitive to the Company's competitive position.
- The document is incorporated by reference into multiple prior Registration Statements on Forms S-8 and F-3.